The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
Open accessAbstract
Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) are important multifunctional cytokines involved in tumour growth and metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-alpha in prostate cancer patients. A total of 80 patients with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-alpha levels were measured and correlated with clinicopathological variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients with recurrent prostate cancer. Serum IL-6 levels in patients with metastatic disease (9.3+/-7.8 pg x ml(-1)) were higher than those in patients with localised disease (1.3+/-0.8 pg x ml(-1), P<0.001). Significantly elevated levels of TNF-alpha were found in metastatic disease (6.3+/-3.6 pg x ml(-1)) compared with localised disease (1.1+/-0.5 pg x ml(-1), P<0.001). The levels of both cytokines were directly correlated with the extent of the disease. Serial analysis in 40 patients with recurrent tumours showed that both cytokines became elevated at the point of prostate-specific antigen progression. In conclusion, these results suggest that IL-6 and TNF-alpha correlate with the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Muenchen, H. J., Lin, D. L., Walsh, M. A., Keller, E. T., & Pienta, K. J. (2000) · PubMed · Cited by 70
RetractedHobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420
ADLER, H. L., McCURDY, M. A., KATTAN, M. W., TIMME, T. L., SCARDINO, P. T., & THOMPSON, T. C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 386
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351
Interleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
Drachenberg, D. E., Elgamal, A.-A. A., Rowbotham, R., Peterson, M., & Murphy, G. P. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19991001)41:2<127::aid-pros7>3.0.co;2-h · Cited by 281
Lou, W., Ni, Z., Dyer, K., Tweardy, D. J., & Gao, A. C. (2000) · The Prostate · doi:10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g · Cited by 278
Interleukin-6 and prostate cancer progression
SMITH, P., HOBISCH, A., LIN, D., CULIG, Z., & KELLER, E. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00021-6 · Cited by 264
Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M. (2001) · Urology · doi:10.1016/s0090-4295(01)01405-4 · Cited by 261 · cited 1×
“IL-6 and TNF-a, two cytokines with multiple and overlapping biological properties, are involved in prostate cancer development (Shariat et al, 2001; Smith et al, 2001).”
Cited by
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
TNF-α in promotion and progression of cancer
Balkwill, F. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9005-3 · Cited by 915
Tumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
Obesity and Prostate Cancer: Weighing the Evidence
Allott, E. H., Masko, E. M., & Freedland, S. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.11.013 · Cited by 601
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, Y., Kimberly, R., Grizzle, W. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6867 · Cited by 425
Metadata
- Authors
- Michalaki, V, Syrigos, K., Charles, P., & Waxman, J.
- Venue
- British Journal of Cancer
- Published
- 2004-05-18
- Volume
- 90
- Issue
- 12
- Pages
- 2312-2316
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2123857513
- Cited by
- 406
- References
- 22
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6601814
- The paper
- Michalaki, V, Syrigos, K., Charles, P., & Waxman, J. (2004). Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
